Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
-$40.24M-49.4%-$56.62M-112%-$19.86M+17.5%-$33.76M-69.0%-$26.93M-53.5%
$198K-22.7%$212K-15.9%$227K-7.0%$265K+1.9%$256K+16.9%
$7.63M+61.2%$7.2M+64.1%$6.96M+72.4%$5.69M+77.4%$4.74M+48.8%
-$41.63M-138%-$41.46M-65.4%-$13.06M+35.5%-$24.7M-71.0%-$17.47M-6.4%
——$78K+255%$86K-70.4%$169K-25.2%$134K-4.3%
$51.06M+190%$25.6M+13.3%$37.94M+80.4%-$174.32M—-$56.78M-7.0%
$1.71M-99.4%$1.41M+2,340%$531K+10,520%$311K+4,343%$270.53M—
$11.14M-94.3%——$25.41M+3,080%-$198.71M—$196.29M+377%
-$41.63M-137%-$41.53M-65.5%-$13.15M+36.0%-$24.87M-69.5%-$17.6M-6.3%

FAQ

How much cash does Rapport Therapeutics, Inc. generate?
Rapport Therapeutics, Inc. (RAPP) generated -$120.9M in operating cash flow over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s free cash flow?
Rapport Therapeutics, Inc.'s free cash flow was -$121.2M over the trailing twelve months, down 55.6% year over year.
Where does Rapport Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.